Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
https://doi.org/10.22416/1382-4376-2020-30-4-23-27
Abstract
Bulevirtide is a novel antiviral agent approved for suppression of chronic hepatitis D but requiring further research into optimising the treatment scheme.
Aim. Comparative assessment of bulevirtide monotherapy versus combined treatment with bulevirtide and pegylat-ed interferon (PEG-IFN) using published trial data.
Key points. MYR201 and MYR203 trials expose a higher frequency of HBsAg and HDV RNA extinction, as well as more effective HDV suppression for combined bulevirtide/PEG-IFN therapy compared to bulevirtide monotherapy.
Conclusion. Combined bulevirtide/PEG-IFN therapy has particular advantages over bulevirtide monotherapy in patients with chronic hepatitis D. Further research is required to optimise bulevirtide dosage and duration of therapy.
About the Authors
V. E. Syutkin
Sklifosovsky Clinical and Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Vladimir E. Syutkin — Dr. Sci. (Med.), Leading Research er, Department of Liver Transplantation, Sklifosovsky Clini cal and Research Institute for Emergency Medicine.
129010, Moscow, Bolshaya Sukharevskaya sq., 3.
A. O. Bueverov
Sechenov First Moscow State Medical University (Sechenov University); Vladimirsky Moscow Regional Research and Clinical Institute
Russian Federation
Russian Federation
Alexey O. Bueverov — Dr. Sci. (Med.), Prof., Department of Medical and Social Expertise, Emergency and Outpatient Medicine, Institute of Vocational Education, Sechenov First Moscow State Medical University (Sechenov University); Leading Researcher, Department of Hepatology, Vladimirsky Moscow Regional Research and Clinical Institute.
119991, Moscow, Trubetskaya str., 8, build. 2.
P. O. Bogomolov
Sklifosovsky Clinical and Research Institute for Emergency Medicine
Russian Federation
Russian Federation
PavelO. Bogomolov — Cand. Sci. (Med.), Head of the Department of Hepatology, Vladimirsky Moscow Regional Research and Clinical Institute.
129110, Moscow, Schepkina str., 61/2.
References
1. Rizzetto M., Hoyer B., Canese M.G., Shih J.W., Purcell R.H., Gerin J.L. Delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci USA. 1980;77(10):6124-8. DOI: 10.1073/pnas.77.10.6124
2. Mentha N., Clement S., Negro F., Alfaiate D. A review on hepatitis D: From virology to new therapies. J Adv Res. 2019;17:3-15. DOI: 10.1016/j.jare.2019.03.009
3. Yan H., Peng B., Liu Y., Xu G., He W., Ren B., et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol. 2014;88(6):3273-84. DOI: 10.1128/JVI.03478-13
4. Bogomolov P., Alexandrov A., Voronkova N., Macievich M., Kokina K., Petrachenkova M., et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490-8. DOI: 10.1016/j.jhep.2016.04.016
5. Wedemeyer H., Bogomolov P., Blank A., Allweiss L., Dandri-Petersen M., Bremer B., et al. Final results of a multicenter, open-label phase2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. Program and abstracts of the International Liver Congress™ 2018 — 53rd annual meeting of the European Association for the Study of the Liver. 2018. Paris, France. GS-005. J Hepatol. 2018;68(Suppl. 1):S3.
6. Wedemeyer H., Schoneweis K., Bogomolov P., Voronkova N., Chulanov V., Stepanova T., et al. Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in combination with PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. Program and abstracts of the The International Liver Congress™ 2019 — 54rd annual meeting of the European Association for the Study of the Liver. 2019. Vienna, Austria GS-13. J Hepatol. 2019;70(Supp. l):e81.
7. https://clinicaltrials.gov/ct2/show/results/NCT02637999?term=NCT02637999&rank=1&view=results
8. Yurdaydin C., Abbas Z., Buti M., Cornberg M., Esteban R., Etzion O., et al. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. J Hepatol. 2019;70(5):1008-15. DOI: 10.1016/j.jhep.2018.12.022
9. Qiu K., Liu B., Li S.Y., Li H., Chen Z.W., Luo A.R., et al. Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance. Aliment Pharmacol Ther. 2018;47(10):1340-8. DOI: 10.1111/apt.14629
Review
For citations:
Syutkin V.E., Bueverov A.O., Bogomolov P.O. Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):23-27. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-4-23-27
Views:
1541
Email this article 
